专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006126864A1 ANIMAL MODELS CARRYING TUMORS EXPRESSING HUMAN PROSTATE CANCER-SPECIFIC ANTIGEN AND METHOD FOR ANALYZING PREVENTION AND TREATMENT EFFICACY OF DENDRITIC CELLS-DERIVED IMMUNOTHERAPEUTICS USING THE ABOVE 审中-公开
标题翻译：携带肿瘤的动物模型表达人前列腺癌特异性抗原和分析预防和治疗使用上述细胞衍生的免疫球蛋白的治疗效果的方法
公开(公告)号：WO2006126864A1
公开(公告)日：2006-11-30
申请号：PCT/KR2006/002028
申请日：2006-05-27
申请人： CREAGENE INC , LEE, Dong Sung , LEE, Woo Bok , JEON, Choon Ju , BAE, Yong Soo
发明人： LEE, Dong Sung , LEE, Woo Bok , JEON, Choon Ju , BAE, Yong Soo
IPC分类号： A01K67/027
CPC分类号： A01K67/0271 , A01K2227/105 , A01K2267/0331
摘要： The present invention relates to a method for analyzing the prevention and treatment efficacy of a dendritic cell- derived immunotherapeutic for prostate cancer using an animal model carrying tumors expressing a human prostate cancer- specific antigen, which comprises the steps of : (a) (a') administering to a normal animal other than human dendritic cells to be analyzed, or (a") administering to a normal animal other than human a cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the normal animal; (b) (b' ) administering to the animal the cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the animal when the step (a' ) is performed in the step (a) , or (b") administering to the animal with cancer dendritic cells to be analyzed when the step (a") is performed in the step (a) ; and (c) determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for prostate cancer by measuring the formation or growth of cancer cells originated from the cancer cell line in the animal.
摘要翻译：本发明涉及使用携带表达人前列腺癌特异性抗原的肿瘤的动物模型分析树突状细胞衍生的前列腺癌免疫治疗剂的预防和治疗功效的方法，其包括以下步骤：（a）（a）对于待分析的人树突细胞以外的正常动物施用，或（a）向表达人前列腺癌特异性抗原的癌细胞系的除人之外的正常动物施用以在正常动物中诱导癌症的（a“） b）（b'）在步骤（a'）或（b“）中施用步骤（a'）或（b”）时向动物施用表达人前列腺癌特异性抗原的癌细胞系以在动物中诱导癌症在步骤（a“）中在步骤（a）中进行分析的具有癌症树突状细胞的动物;和（c）通过测定来确定树突状细胞作为前列腺癌的免疫治疗剂的预防和治疗功效环绕来自动物的癌细胞系的癌细胞的形成或生长。

2. 发明申请

WO2003082891A1 NOVEL DENDRITIC CELL-SPECIFIC POLYNUCLEOTIDES AND MICROARRAY COMPRISING THE SAME 审中-公开
标题翻译：新颖的细胞特异性多核苷酸和包含其的微阵列
公开(公告)号：WO2003082891A1
公开(公告)日：2003-10-09
申请号：PCT/KR2003/000631
申请日：2003-03-28
申请人： CREAGENE INC. , LEE, Sang-Jin , AHN, Jung-Hoon , LEE, Yoon , JEON, Choon-Ju , LEE, Byung-Hak , CHOI, Kang-Duk , BAE, Yong-Soo
发明人： AHN, Jung-Hoon , LEE, Yoon , JEON, Choon-Ju , LEE, Byung-Hak , CHOI, Kang-Duk , BAE, Yong-Soo
IPC分类号： C07H21/00
CPC分类号： C07H21/00
摘要： The present invention relates to dentritic cell-specific polynucleotides and microarrays, particularly to novel polynucleotides highly expressed in dendritic cells, certain dendritic cell subsets and matured dendritic cells and microarrays comprising thereof. With a marrcoarray of this invention, dendritic cells, certain dendritic cells subsets and matured dendritic cells can be detected rapidly and accurately.
摘要翻译：本发明涉及树突细胞特异性多核苷酸和微阵列，特别涉及在树突细胞中高度表达的新型多核苷酸，某些树突状细胞亚群和成熟树突状细胞以及包含其的微阵列。利用本发明的糖浆体，可以快速，准确地检测树突状细胞，某些树状细胞亚群和成熟的树突状细胞。

3. 发明申请

WO2009008666A2 AUTOLOGOUS DENDRITIC CELL MEDIATED BY PHOTODYNAMIC THERAPY HAVING THE ABILITY TO SUPPRESS THE GROWTH OF TUMOR 审中-公开
标题翻译：通过光动力疗法介导的自体树突状细胞具有抑制肿瘤生长的能力
公开(公告)号：WO2009008666A2
公开(公告)日：2009-01-15
申请号：PCT/KR2008/004042
申请日：2008-07-09
申请人： CREAGENE INC. , KANG, Mi-Sun , LIM, Dae-Seog , JEONG, Ju-Ah , LEE, Hyun-Soo , BAE, Yong-Soo
发明人： LIM, Dae-Seog , JEONG, Ju-Ah , LEE, Hyun-Soo , BAE, Yong-Soo
IPC分类号： C12N5/06
CPC分类号： C12N5/0639 , A61K2035/124 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/25 , C12N2502/30
摘要： The present invention relates to mature dendritic cells (DCs) having the enhanced ability to induce anti-tumor immune responses, and to a method for the preparation of the above-mentioned DCs through the procedure of pulsing immature DCs with lysates of cancer cells on which photodynamic therapy (PDT) has been conducted. The dendritic cell of this invention acquires an activity to induce anti-tumor immune responses so that it exerts a remarkable effect to suppress the growth of tumor.
摘要翻译：本发明涉及具有增强的诱导抗肿瘤免疫应答能力的成熟树突细胞（DC），并且涉及通过脉冲未成熟的程序制备上述DC的方法具有已经进行了光动力治疗（PDT）的癌细胞裂解物的DC。本发明的树突状细胞获得诱导抗肿瘤免疫应答的活性，从而发挥显着的抑制肿瘤生长的作用。

4. 发明申请

WO2003097671A1 CYTOPLASMIC TRANSDUCTION PEPTIDES AND USES THEREOF 审中-公开
标题翻译： CYTOPLASMIC TRANSDUCTION PEPTIDES及其用途
公开(公告)号：WO2003097671A1
公开(公告)日：2003-11-27
申请号：PCT/KR2003/000630
申请日：2003-03-28
申请人： CREAGENE INC. , KIM, Dae-You , OH, Hae-Keun , KIM, Chang-Hyun , KIM, Jung-Hwan , JEON, Choon-Ju , KIM, Ki-Tae , BAE, Yong-Soo , CHOI, In-Soo
发明人： KIM, Dae-You , OH, Hae-Keun , KIM, Chang-Hyun , KIM, Jung-Hwan , JEON, Choon-Ju , KIM, Ki-Tae , BAE, Yong-Soo , CHOI, In-Soo
IPC分类号： C07K7/06
摘要： The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
摘要翻译：本发明涉及显示转导电位的细胞质转导肽（CTP），以及细胞质剩余电位及其各种用途。本发明的CTP显示出与常规蛋白转导（PTD）相同或更高的转导电位，并且具有保留在细胞质中的强烈倾向，因此其在诱导细胞毒性T淋巴细胞（CTL）和药物递送系统 DDS）靶向细胞质。

5. 发明申请

WO2002087626A1 PHARMACEUTICAL COMPOSITIONS COMPRISING DENDRITIC CELLS FOR IMMUNOTHERAPY OF AUTOIMMUNE DISEASE AND TREATMENT METHODS USING THE SAME 审中-公开
标题翻译：包含自体免疫疾病免疫治疗的细胞的药物组合物和使用其的治疗方法
公开(公告)号：WO2002087626A1
公开(公告)日：2002-11-07
申请号：PCT/KR2002/000780
申请日：2002-04-26
申请人： CREAGENE INC. , SUNGAE BIOTECH INC. , BAE, Yong-Soo , JEON, Choon-Ju , LEE, Yoon , SONG, Ki-Duk , KIM, Chang-Hyun , KIM, Il-Soo , CHO, Hyun-Pil , DO, Seon-Gil , NAM, Hye-Jung , PARK, Jai-Kyung
发明人： BAE, Yong-Soo , JEON, Choon-Ju , LEE, Yoon , SONG, Ki-Duk , KIM, Chang-Hyun , KIM, Il-Soo , CHO, Hyun-Pil , DO, Seon-Gil , NAM, Hye-Jung , PARK, Jai-Kyung
IPC分类号： A61K48/00
CPC分类号： C12N5/064 , A61K2035/122 , A61K2039/5154 , C12N2501/24
摘要： The present invention relates to a pharmaceutical composition for immunotherapy of autoimmune disease, which comprises (a) a therapeutically effective dose of maturated dendritic cells and (b) a pharmaceutically acceptable carrier and a method for immunotherapy of autoimmune disease.
摘要翻译：本发明涉及用于自身免疫疾病的免疫治疗的药物组合物，其包含（a）治疗有效剂量的成熟树突状细胞和（b）药学上可接受的载体和自身免疫疾病的免疫治疗方法。

6. 发明申请

WO2008143400A1 ANIMAL MODELS CARRYING TUMORS EXPRESSING HUMAN LIVER CANCER-SPECIFIC ANTIGEN AND METHOD FOR ANALYZING PREVENTION AND TREATMENT EFFICACY OF DENDRITIC CELLS-DERIVED IMMUNOTHERAPEUTICS USING THE ABOVE 审中-公开
标题翻译：携带肿瘤的动物模型表达人肝癌特异性抗原和分析预防和治疗使用上述细胞衍生的免疫球蛋白的效果的方法
公开(公告)号：WO2008143400A1
公开(公告)日：2008-11-27
申请号：PCT/KR2008/001420
申请日：2008-03-13
申请人： CREAGENE INC. , BAE, Yong-Soo , LEE, Hyun-Soo , MIN, Mi-Kyung , JEONG, Cheol-Woong , KANG, Kyu-Ho
发明人： BAE, Yong-Soo , LEE, Hyun-Soo , MIN, Mi-Kyung , JEONG, Cheol-Woong , KANG, Kyu-Ho
IPC分类号： C12Q1/00
CPC分类号： G01N33/57438 , A61K35/12 , A61K39/0011 , A61K2039/5154 , A61K2039/6075 , C07K14/4748 , C12N2799/027
摘要： The present invention relates to a method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for liver cancer using an animal model carrying tumors expressing a human liver cancer-specific antigen, which comprises the steps of : (a) (a1) administering to a normal animal other than human dendritic cells to be analyzed, or (a1) administering to a normal animal other than human a cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the normal animal; (b) (b1) administering to the animal the cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the animal when the step (a1) is performed in the step (a), or (b1) administering to the animal with cancer dendritic cells to be analyzed when the step (a1) is performed in the step (a); and (c) determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for liver cancer by measuring the formation or growth of cancer cells originated from the cancer cell line in the animal.
摘要翻译：本发明涉及使用携带表达人肝癌特异性抗原的肿瘤的动物模型分析来自树突状细胞的免疫治疗用于肝癌的预防和治疗功效的方法，其包括以下步骤：（a）（a1））给予除了待分析的人树突状细胞以外的正常动物，或（a1）向正常动物中的表达人肝癌特异性抗原的癌细胞系的人以外的正常动物施用癌细胞系，（b）（b1）当在步骤（a）中进行步骤（a1）时，（b1）向动物施用表达人肝癌特异性抗原的癌细胞系以在动物中诱导癌症，或（b1）当在步骤（a）中进行步骤（a1）时，分析具有癌症树突状细胞的动物; 和（c）通过测量起源于动物的癌细胞系的癌细胞的形成或生长来确定树突状细胞作为肝癌的免疫治疗剂的预防和治疗功效。

7. 发明申请

WO2008102937A1 MESENCHYMAL STEM CELL-MEDIATED AUTOLOGOUS DENDRITIC CELLS WITH INCREASED IMMUNOSUPPRESSION 审中-公开
标题翻译：间质干细胞介导的自体免疫细胞增殖免疫抑制
公开(公告)号：WO2008102937A1
公开(公告)日：2008-08-28
申请号：PCT/KR2007/003681
申请日：2007-07-31
申请人： CREAGENE INC. , LIM, Dae Seog , JEONG, Ju Ah , KANG, Mi-Sun , LEE, Hyun Soo , BAE, Yong Soo
发明人： LIM, Dae Seog , JEONG, Ju Ah , KANG, Mi-Sun , LEE, Hyun Soo , BAE, Yong Soo
IPC分类号： C12N5/06 , C12N5/08 , C12N5/00 , A61P37/02
CPC分类号： C12N5/064 , A61K2035/122 , C12N2502/1358
摘要： The present invention relates to a method for preparing dendritic cells which have an enhanced potential to suppress immune responses, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells of this invention ensures the cells to be effectively used as an immunosuppressive agent.
摘要翻译：本发明涉及一种制备树突细胞的方法，该方法具有增强的抑制免疫应答的潜力，具有抑制免疫应答潜力的树突状细胞，以及包含能诱导免疫抑制反应的树突状细胞的药物组合物。具有增强的抑制免疫应答潜力的本发明的树突状细胞可用于通过抑制免疫应答来治疗各种疾病或病症。此外，本发明的树突细胞的增强的免疫耐受潜力确保细胞被有效地用作免疫抑制剂。

8. 发明申请

WO2007129858A1 NOVEL USE OF MLN51 GENE AND PROTEIN 审中-公开
标题翻译：新的使用MLN51基因和蛋白质
公开(公告)号：WO2007129858A1
公开(公告)日：2007-11-15
申请号：PCT/KR2007/002259
申请日：2007-05-08
申请人： CREAGENE INC. , JANG, Jin Ah , LIM, Dae Seog , LEE, Hyun Soo , BAE, Yong Soo
发明人： JANG, Jin Ah , LIM, Dae Seog , LEE, Hyun Soo , BAE, Yong Soo
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.
摘要翻译：本发明涉及MLN 51基因或蛋白质的新用途。 MLN 51基因和蛋白质与类风湿性关节炎的发展密切相关，作为类风湿性关节炎，特别是慢性滑膜炎的生物标志物和治疗靶点。

9. 发明申请

WO2009008666A3 AUTOLOGOUS DENDRITIC CELL MEDIATED BY PHOTODYNAMIC THERAPY HAVING THE ABILITY TO SUPPRESS THE GROWTH OF TUMOR 审中-公开
标题翻译：具有抑制肿瘤生长的能力的光动力治疗介导的自动细胞细胞
公开(公告)号：WO2009008666A3
公开(公告)日：2009-03-19
申请号：PCT/KR2008004042
申请日：2008-07-09
申请人： CREAGENE INC , KANG MI SUN , LIM DAE-SEOG , JEONG JU-AH , LEE HYUN-SOO , BAE YONG-SOO
发明人： LIM DAE-SEOG , JEONG JU-AH , LEE HYUN-SOO , BAE YONG-SOO
IPC分类号： C12N5/0784
CPC分类号： C12N5/0639 , A61K2035/124 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/25 , C12N2502/30
摘要： The present invention relates to mature dendritic cells (DCs) having the enhanced ability to induce anti-tumor immune responses, and to a method for the preparation of the above-mentioned DCs through the procedure of pulsing immature DCs with lysates of cancer cells on which photodynamic therapy (PDT) has been conducted. The dendritic cell of this invention acquires an activity to induce anti-tumor immune responses so that it exerts a remarkable effect to suppress the growth of tumor.
摘要翻译：本发明涉及具有增强的抗肿瘤免疫应答能力的成熟树突状细胞（DCs），以及通过以下步骤制备上述DC的方法：通过以下步骤将不成熟的DC脉冲化：癌细胞的裂解物光动力疗法（PDT）已经进行。本发明的树突细胞获得诱导抗肿瘤免疫应答的活性，从而具有显着的抑制肿瘤生长的作用。

10. 发明申请

WO2008130100A1 SEMI-MATURE DENTRITIC CELL 审中-公开
标题翻译：半成熟细胞
公开(公告)号：WO2008130100A1
公开(公告)日：2008-10-30
申请号：PCT/KR2008/001397
申请日：2008-03-12
申请人： CREAGENE INC. , KANG, Mi-Sun , LIM, Dae-Seog , JEONG, Ju-Ah , LEE, Hyun-Soo , BAE, Yong-Soo
发明人： KANG, Mi-Sun , LIM, Dae-Seog , JEONG, Ju-Ah , LEE, Hyun-Soo , BAE, Yong-Soo
IPC分类号： A61K35/14 , C12N5/00 , A61K48/00
CPC分类号： A61K39/0008 , A61K2035/122 , A61K2039/5154 , C12N5/064 , C12N2501/22 , C12N2501/25
摘要： The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis through the activity of the suppression of auto-immune responses.
摘要翻译：本发明涉及一种用于治疗类风湿性关节炎的药物组合物，其包含（a）药学有效量的半成熟树突状细胞; 和（b）药学上可接受的载体。本发明的半成熟树突状细胞通过抑制自身免疫应答的活性具有安全和显着改善的治疗或预防类风湿性关节炎的潜力。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式